The Henry M. Jackson Foundation for the Advancement of Military Medicine will fund work.
GenVec and the U.S. Naval Medical Research Center (NMRC) have entered into a CRADA to support NMRC’s dengue fever vaccine research. Under a separate contract with the Henry M. Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to this program.
The company anticipates that it will recognize approximately $530,000 of revenue associated with the completion of work under the agreement with the Jackson Foundation, which is expected this year.
GenVec will be responsible for designing and manufacturing candidates using its adenovector technology. The vaccines will be manufactured utilizing GenVec's cell line. NMRC will be responsible for preclinical animal studies including studies in nonhuman primates.